These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 28488141)

  • 21. Regulation and characterization of tumor-infiltrating immune cells in breast cancer.
    Dai Q; Wu W; Amei A; Yan X; Lu L; Wang Z
    Int Immunopharmacol; 2021 Jan; 90():107167. PubMed ID: 33223469
    [TBL] [Abstract][Full Text] [Related]  

  • 22. T-cell activation is associated with high-grade serous ovarian cancer survival.
    Wang L; Sun W; Zhang G; Huo J; Tian Y; Zhang Y; Yang X; Liu Y
    J Obstet Gynaecol Res; 2022 Aug; 48(8):2189-2197. PubMed ID: 35334503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment.
    Syed Khaja AS; Toor SM; El Salhat H; Faour I; Ul Haq N; Ali BR; Elkord E
    Oncotarget; 2017 May; 8(20):33159-33171. PubMed ID: 28388539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
    Pollack SM; He Q; Yearley JH; Emerson R; Vignali M; Zhang Y; Redman MW; Baker KK; Cooper S; Donahue B; Loggers ET; Cranmer LD; Spraker MB; Seo YD; Pillarisetty VG; Ricciotti RW; Hoch BL; McClanahan TK; Murphy E; Blumenschein WM; Townson SM; Benzeno S; Riddell SR; Jones RL
    Cancer; 2017 Sep; 123(17):3291-3304. PubMed ID: 28463396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression and prognostic significance of programmed death protein 1 and programmed death ligand-1, and cytotoxic T lymphocyte-associated molecule-4 in hepatocellular carcinoma.
    Chang H; Jung W; Kim A; Kim HK; Kim WB; Kim JH; Kim BH
    APMIS; 2017 Aug; 125(8):690-698. PubMed ID: 28493410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ.
    Moran AE; Polesso F; Weinberg AD
    J Immunol; 2016 Sep; 197(6):2509-21. PubMed ID: 27503208
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic impact of immune microenvironment in laryngeal and pharyngeal squamous cell carcinoma: Immune cell subtypes, immuno-suppressive pathways and clinicopathologic characteristics.
    Karpathiou G; Casteillo F; Giroult JB; Forest F; Fournel P; Monaya A; Froudarakis M; Dumollard JM; Prades JM; Peoc'h M
    Oncotarget; 2017 Mar; 8(12):19310-19322. PubMed ID: 28038471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
    Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
    Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases.
    Harter PN; Bernatz S; Scholz A; Zeiner PS; Zinke J; Kiyose M; Blasel S; Beschorner R; Senft C; Bender B; Ronellenfitsch MW; Wikman H; Glatzel M; Meinhardt M; Juratli TA; Steinbach JP; Plate KH; Wischhusen J; Weide B; Mittelbronn M
    Oncotarget; 2015 Dec; 6(38):40836-49. PubMed ID: 26517811
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1
    Dovedi SJ; Elder MJ; Yang C; Sitnikova SI; Irving L; Hansen A; Hair J; Jones DC; Hasani S; Wang B; Im SA; Tran B; Subramaniam DS; Gainer SD; Vashisht K; Lewis A; Jin X; Kentner S; Mulgrew K; Wang Y; Overstreet MG; Dodgson J; Wu Y; Palazon A; Morrow M; Rainey GJ; Browne GJ; Neal F; Murray TV; Toloczko AD; Dall'Acqua W; Achour I; Freeman DJ; Wilkinson RW; Mazor Y
    Cancer Discov; 2021 May; 11(5):1100-1117. PubMed ID: 33419761
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model.
    Yshii LM; Gebauer CM; Pignolet B; Mauré E; Quériault C; Pierau M; Saito H; Suzuki N; Brunner-Weinzierl M; Bauer J; Liblau R
    Brain; 2016 Nov; 139(11):2923-2934. PubMed ID: 27604307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic impact of high levels of circulating plasmacytoid dendritic cells in breast cancer.
    Kini Bailur J; Gueckel B; Pawelec G
    J Transl Med; 2016 May; 14(1):151. PubMed ID: 27234566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic polymorphisms and surface expression of CTLA-4 and PD-1 on T cells of silica-exposed workers.
    Rocha MC; Santos LM; Bagatin E; Cohen Tervaert JW; Damoiseaux JG; Lido AV; Longhini AL; Torello CO; Queiroz ML
    Int J Hyg Environ Health; 2012 Nov; 215(6):562-9. PubMed ID: 22153879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
    Allard B; Pommey S; Smyth MJ; Stagg J
    Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CTLA‑4 blockade combined with 5‑aza‑2'‑deoxycytidine enhances the killing effect of MAGE‑A family common antigen peptide‑specific cytotoxic T cells on breast cancer.
    Li W; Sang M; Hao X; Wu Y; Shan B
    Oncol Rep; 2020 Oct; 44(4):1758-1770. PubMed ID: 32700745
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer.
    Zheng H; Liu X; Zhang J; Rice SJ; Wagman M; Kong Y; Zhu L; Zhu J; Joshi M; Belani CP
    Oncotarget; 2016 Aug; 7(35):56233-56240. PubMed ID: 27191652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of genetic variation in co-stimulatory molecule genes with outcome of liver transplant in Iranian patients.
    Karimi MH; Motazedian M; Abedi F; Yaghobi R; Geramizadeh B; Nikeghbalian S
    Gene; 2012 Aug; 504(1):127-32. PubMed ID: 22579879
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PD-1/PD-L1 Pathway in Breast Cancer.
    Schütz F; Stefanovic S; Mayer L; von Au A; Domschke C; Sohn C
    Oncol Res Treat; 2017; 40(5):294-297. PubMed ID: 28346916
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phenotypic Characteristics of PD-1 and CTLA-4 Expression in Symptomatic Acute Hepatitis A.
    Cho H; Kang H; Kim CW; Kim HY; Jang JW; Yoon SK; Lee CD
    Gut Liver; 2016 Mar; 10(2):288-94. PubMed ID: 26347518
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
    Darb-Esfahani S; Kunze CA; Kulbe H; Sehouli J; Wienert S; Lindner J; Budczies J; Bockmayr M; Dietel M; Denkert C; Braicu I; Jöhrens K
    Oncotarget; 2016 Jan; 7(2):1486-99. PubMed ID: 26625204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.